황반변성·망막

30개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved30 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 244Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 234Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
CGTAAVCurated CoreFDAstaleSpark TherapeuticsApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 7Status Approved
AntibodyLimited DatastaleJanssenPhase 3

infliximab (Remicade, Remicade (infliximab))

Uveitis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 90Status Active
CGTCurated CorestaleREGENXBIO Inc.Phase 2

RGX-314 (RGX-314)

Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#BioJungboMoa-pick#cell-gene-therapy+4
Trials 12Status Active
CGTLimited DatastaleFrontera TherapeuticsPhase 2

FT-003 (FT-003)

Diabetic Macular Edema · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTLimited DatastaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy product:vMCO-I (Gene Therapy product:vMCO-I)

Retinitis Pigmentosa; Retinal Diseases · Retinitis Pigmentosa

#RetinitisPigmentosa#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTAAVLimited DatastaleGenentech, Inc.Preclinical

AAV2-hRPE65v2 (AAV2-hRPE65v2)

Inherited Retinal Dystrophy Due to RPE65 Mutations · Multi-target

#Multi-target#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleGenzyme, a Sanofi CompanyPhase 1

AAV2-sFLT01 (AAV2-sFLT01)

Macular Degeneration; Age-Related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleJanssen Research & Development,…Phase 1

AAVCAGsCD59 (AAVCAGsCD59)

Dry Age-related Macular Degeneration · Dry Age-related Macular Degeneration

#DryAge-relatedMacularDegeneratio#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Active bevacizumab and Active dexamethasone (Active bevacizumab and Active dexamethasone)

Non-Ischemic Central Retinal Vein Occlusion · Non-Ischemic Central Retinal Vein Occlus

#Non-IschemicCentralRetinalVeinOc#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

ranibizumab (Lucentis, Bevacizumab, Ranibizumab)

Retinopathy of Prematurity Both Eyes · Retinopathy of Prematurity Both Eyes

#RetinopathyofPrematurityBothEyes#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleNational Eye Institute (NEI)Phase 1

Zenapax (Daclizumab, Daclizumab (Zenapax))

Uveitis · Uveitis

#Uveitis#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Active
CGTAAVLimited DatastaleElisigen, Inc.Phase 2

NG101 AAV gene therapy (NG101 AAV gene therapy)

Age-Related Macular Degeneration · Age-Related Macular Degeneration

#Age-RelatedMacularDegeneration#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Discontinued
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#ClinicalStageIVCutaneousMelanoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleSaglik Bilimleri UniversitesiPreclinical

ranibizumab (Lucentis, dexamethasone implant versus ranibizumab)

Diabetic Macular Edema; Inflammation · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Inflammation+1
Trials 1Status Active

1 / 2 pages

← PreviousNext →